Clinical Trial: A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07736612) titled 'A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer' on July 27.

Brief Summary: This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.

Study Start Date: Aug. 15

Study Type: INTERVENTIONAL

Condition: Pancreatic Cancer RAS Mutations or Amplifications

Intervention: DRUG: HRS-2329 Tablet

HRS-2329 is a novel, potent, oral pan-RAS inhibitor that demonstrates strong inhibitory activity against a broad range of RAS-relat...